Febrile Neutropenia — Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report — 2023 To 2033
Neutropenic fever is characterized by a single oral temperature of 101°F (38.3°C) or more or a consistent temperature of 100.4°F (38°C) for at least an hour, in conjunction with an absolute neutrophil count (ANC) of less than 1500 cells/microliter. Identifying the exact cause of the infection is often challenging, leading to it being categorized as a fever of unknown origin (FUO). This classification is used for neutropenic cases where the fever exceeds 38.3°C, and there’s no clinical or microbiological evidence of infection. Neutropenic fever is a common and severe complication in patients with hematopoietic cancers or those receiving chemotherapy. It occurs when an infectious agent encounters a neutropenic patient. The diagnostic process involves extensive blood tests, including a complete blood count to evaluate neutropenic levels and blood, urine, and throat cultures to determine the source of the infection. In outpatient settings, low-risk patients are treated empirically with oral fluoroquinolone combined with amoxicillin/clavulanate. On the other hand, high-risk patients with neutropenic fever require immediate initiation of intravenous antibiotic therapy within one hour of triage, followed by close monitoring for at least four hours before discharge.
- In March 2023, the FDA approved a single-dose, prefilled autoinjector of pegfilgrastim-cbqv. This is administered the day after chemotherapy to decrease the occurrence of infection, as shown by febrile neutropenia.
Thelansis’s “Febrile Neutropenia Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report — 2023 To 2033” covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Febrile Neutropenia treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).
KOLs insights of Febrile Neutropenia across 8 MM market from the centre of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm, and Unmet needs.
Febrile Neutropenia Market Forecast Patient Based Forecast Model (MS. Excel Based Automated Dashboard), which Data Inputs with sourcing, Market Event, and Product Event, Country specific Forecast Model, Market uptake and patient share uptake, Attribute Analysis, Analog Analysis, Disease burden, and pricing scenario, Summary, and Insights.
Thelansis Competitive Intelligence (CI) practice has been established based on a deep understanding of the pharma/biotech business environment to provide an optimized support system to all levels of the decision-making process. It enables business leaders in forward-thinking and proactive decision-making. Thelansis supports scientific and commercial teams in seamless CI support by creating an AI/ ML-based technology-driven platform that manages the data flow from primary and secondary sources.
